Axiom Bio
AI NativeEliminate molecular toxicity with AI models which outperform physical experiments
Est 2024|Valuation $121M|Raised $30M
Eliminate molecular toxicity with AI models which outperform physical experiments
Published Sep 17, 2026
Many unrelated companies use "Axiom" or similar names across other domains (finance, IAM, crypto, clinical software). Review platform results often reference other organizations, not Axiom Bio (the vendor). This makes it difficult to identify independent user reviews for the specific company under review.
As of March 9, 2026, credible third-party end-user reviews specifically attributable to Axiom Bio (the vendor) were not found on G2, TrustRadius, or Gartner Peer Insights in the accessible searches.
Available public material consists primarily of vendor-authored content (benchmarks, investor memo, blog) and press coverage of the company and its seed funding.
Axiom’s investor and company materials state that prospective customers expressed preference for the vendor’s approach. These are vendor-sourced statements and were not accompanied by independently verifiable, named customer references in the accessible materials.
Evaluators should treat the lack of independent review coverage as a diligence risk and should request:
Inferred best-fit:
Decision makers:
End users:
Get a comprehensive analysis of Axiom Bio including market position, competitive landscape, adoption trends, and peer benchmarks.
Download full report →The vendor publishes benchmark comparisons between its liver model and certain in vitro assay baselines. Example vendor-presented metrics include:
Critical evaluation:
Press reporting references a curated clinical toxicity dataset and vendor-reported per-compound cost claims. Public articles repeat vendor statements but do not provide full provenance for the dataset or independent validation of economic comparisons.
Critical evaluation:
Axiom Bio provides a platform that combines experimental data from primary human hepatocytes with statistical and machine learning models to predict human drug-induced liver injury (DILI) during discovery and preclinical development. The system integrates high-content imaging, biochemical assays, and interpretability features into a web application for risk assessment, visualization, and decision support for lead optimization and candidate selection.
Primary stated aim: estimate clinical liver risk earlier in discovery to support decision-making by indicating compounds with elevated DILI risk relative to common in vitro assays.
Target customers appear to include:
Positioning: the product uses data derived from human primary cells plus statistical and machine-learning models to produce liver risk estimates that are presented as tied to exposure estimates. This aligns with industry interest in alternatives to animal testing and with efforts to incorporate human-cell-derived evidence into early safety assessment.